Phase I Study of Paclitaxel in Combination With a Multidrug Resistance Modulator, PSC 833 (Valspodar), in Refractory Malignancies

BIOCHEMISTRY OF MULTIDRUG RESISTANCE MEDIATED BY THE MULTIDRUG TRANSPORTER

1993 • 3,515 citations

THE DEVELOPMENT AND CLINICAL UTILITY OF THE TAXANE CLASS OF ANTIMICROTUBULE CHEMOTHERAPY AGENTS

1997 • 721 citations

Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans.

1995 • 550 citations

A program package for simulation and parameter estimation in pharmacokinetic systems

1979 • 483 citations

In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833.

1991 • 364 citations

Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance.

1992 • 298 citations

Clinical relevance of transmembrane drug efflux as a mechanism of multidrug resistance.

1998 • 221 citations

Phase I trial of etoposide with cyclosporine as a modulator of multidrug resistance.

1992 • 221 citations

Resistance modification by PSC-833, a novel non-immunosuppressive cyclosporin A

1991 • 218 citations

Cyclosporins as drug resistance modifiers

1992 • 205 citations

Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance.

1994 • 186 citations

Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer.

1996 • 179 citations

Clinical Studies with Modulators of Multidrug Resistance

1995 • 163 citations

Phase I trial of 3-hour infusion of paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer.

1994 • 136 citations

Restoration of daunomycin retention in multidrug-resistant P388 cells by submicromolar concentrations of SDZ PSC 833, a nonimmunosuppressive cyclosporin derivative

1991 • 126 citations

Paclitaxel pharmacokinetics and pharmacodynamics.

1995 • 123 citations

SDZ PSC 833, A non‐immunosuppressive cyclosporine: Its potency in overcoming P‐glycoprotein‐mediated multidrug resistance of murine leukemia

1992 • 112 citations

Paclitaxel Disposition in Plasma and Central Nervous Systems of Humans and Rats With Brain Tumors

1995 • 110 citations

Multidrug resistance in human cancer

1992 • 103 citations

Phase I pharmacokinetic study of cyclosporin A combined with doxorubicin.

1993 • 91 citations

SDZ PSC 833, a non-immunosuppressive cyclosporin analog, is a very potent multidrug-resistance modifier

1991 • 87 citations

A dose-finding and pharmacokinetic study of reversal of multidrug resistance with SDZ PSC 833 in combination with doxorubicin in patients with solid tumors.

1997 • 87 citations

Feasibility and pharmacokinetics of paclitaxel, carboplatin, and concurrent radiotherapy for regionally advanced squamous cell carcinoma of the head and neck and for regionally advanced non-small cell lung cancer.

1995 • 24 citations